Literature DB >> 10761560

The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection.

E H Sasso1.   

Abstract

Studies of mixed cryoglobulins (MC) from patients infected with hepatitis C virus (HCV) show that the principal constituents in cryoprecipitate are IgM rheumatoid factors (RF), polyclonal IgG anti-HCV antibodies, and HCV RNA. The HCV-induced RF response is biased to produce IgM RF encoded by a restricted set of Ig V genes, predominantly the VH/VL gene pair 51p1/kv325. The propensity of such IgM RF to cryoprecipitate is likely a coincidental property of their V region sequences, but the clinical effect of this bias is increased by the persistence of circulating HCV-IgG immune complexes. These complexes might induce production of cryoprecipitable IgM RF and furnish multi-molecular structures that favor binding by cryoprecipitable IgM RF. The V gene sequences of HCV-induced IgM RF have features seen in other RF responses, suggesting a common immunological mechanism that is independent of HCV. B cell proliferation is probably enhanced by HCV-specific properties, however, including the ability of HCV proteins to bind to CD81 on the B cell surface, and to influence intracellular regulatory functions following viral entry into B cells. The V gene bias in HCV-induced RF is most apparent among the B cells in monoclonal expansions responsible for type II cryoglobulins, but it might originate early the polyclonal RF response, before MC are detectable. Monoclonal B cell expansions and lymphomatoid bone marrow infiltrates in HCV+ patients predominantly involve CD5-negative IgM RF B cells. Non-RF B cells can also be expanded, including producers of IgG1 and IgG3 that are likely anti-HCV antibodies. The initial site of B cell clonal expansion may be in the liver, where lymphoid aggregates are abundant and RF are produced. Sorting out how MC formation is influenced by properties that are inherent to the RF response, or specific to HCV infection, will be a challenge to future HCV research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761560

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  8 in total

1.  Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.

Authors:  C Dumestre-Perard; D Ponard; C Drouet; V Leroy; J-P Zarski; N Dutertre; M G Colomb
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

2.  Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection.

Authors:  E Zuckerman; G Slobodin; A Kessel; E Sabo; D Yeshurun; K Halas; E Toubi
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.

Authors:  Eli Zuckerman; Aharon Kessel; Gleb Slobodin; Edmond Sabo; Daniel Yeshurun; Elias Toubi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Effect of 51p1-related gene copy number (V1-69 locus) on production of hepatitis C-associated cryoglobulins.

Authors:  E H Sasso; P Ghillani; L Musset; J C Piette; P Cacoub
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

6.  Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment.

Authors:  Elias Toubi; Aharon Kessel; Regina Peri; Zehava Shmuel; Ellen Bamberger; Edmond Sabo; Eli Zuckerman
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 7.  Systemic abnormalities in liver disease.

Authors:  Masami Minemura; Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

Review 8.  A juggernaut of innate & adaptive immune cells in chronic hepatitis C.

Authors:  Shallu Tomer; Sunil K Arora
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.